Publisert 29.11.2018

Notification of grant:Divisional EPO patent

Notification of grant: Divisional EPO patent

 

Regenics have recieved notification from the European Patent Office on November 22nd 2018 of EPOs granting of  a Decision to Grant from the European Patent Office for the EP Patent Application No. 12178381.5    Divisional of EP Patent Application No. 07825530.4

Entitled: ADMINISTRATION OF CELLS  AND CELLULAR EXTRACTS FOR REJUVENATION

The application will grant on December 19, 2018 as EP Patent Number 

2656832.

Additional info on our other EPO patents: EP 2296676.  09742464.2

For more information, please contact Henrik Lund, CEO

 

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.